In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.23 below Immucell Corporation average.

Within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Quick Ratio than Immucell in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1158 to 1636.

Explain Quick Ratio?
How much Cash & cash equivalents ICCC�s has?
What are ICCC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ICCC/financial-strength

https://api.csimarket.com/api/v1/companies/ICCC/fundamentals

https://api.csimarket.com/api/v1/companies/ICCC/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ICCC Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	61.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	103.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.23	Subscribe	Subscribe	Subscribe	Subscribe
ICCC's Total Ranking	# 1636	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	10.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-10.67 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 8
Healthcare Sector	# 563
Overall Market	# 1636

Quick Ratio Statistics
High	Average	Low
19.26	4.93	0
(Dec 31 2016)		(Mar 31 2022)

Financial Statements
Immucell's Current Liabilities	$ 6 Millions	Visit ICCC's Balance sheet
Immucell's Cash & cash equivalent	$ 8 Millions	Visit ICCC's Balance sheet
Source of ICCC's Sales		Visit ICCC's Sales by Geography

Cumulative Immucell's Quick Ratio

ICCC's Quick Ratio for the trailling 12 Months

ICCC Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	17.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	604.91 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.28	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1410	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	13.02 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	17.24 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ICCC Financial Strength Comparisons >> Go to Compare ICCC Quick Ratio to its Competitors

On the trailing twelve months basis ICCC Cash & cash equivalent more than doubled by 103.65 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Immucell's Quick Ratio to 1.28, Quick Ratio remained below ICCC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Immucell. While Quick Ratio overall ranking has improved so far to 3892, from total ranking during the twelve months ending second quarter 2026 at 3993.

Explain Quick Ratio?
How much Cash & cash equivalents ICCC�s has?
What are ICCC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 887
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.99	2.41	0.08
		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Lantheus Holdings Inc	1.98	$ 683.610 Millions	$ 345.967 Millions
Alpha Teknova Inc	1.86	$ 16.560 Millions	$ 8.926 Millions
Immucell Corporation	1.23	$ 7.914 Millions	$ 6.460 Millions
Biomerica Inc	0.96	$ 2.733 Millions	$ 2.837 Millions
Myriad Genetics Inc	0.78	$ 107.100 Millions	$ 137.600 Millions

Date modified: 2026-11-13T07:24:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.